Inhibition of MDA-MB-231 human breast tumor xenografts and HER2 expression by anti-tumor agents GAP31 and MAP30

Sylvia Lee-Huang, Philip L. Huang, Yongtao Sun, Hao Chia Chen, Hsiang Fu Kung, Paul L. Huang, William J Murphy

Research output: Contribution to journalArticlepeer-review

70 Scopus citations


GAP31 (Gelonium protein of 31 kDa) and MAP30 (Momordica protein of 30 kDa) are agents isolated from the medicinal plants Gelonium multiflorum and Momordica charantia, respectively. The current study was conducted to investigate the efficacy of GAP31 and MAP30 on estrogen-independent and highly metastatic human breast tumor MDA-MB-231 both in vitro and in vivo. The effect of these agents on the expression of breast tumor antigen HER2 (also known as neu or as c-erbB 2) was also examined. Treatment of MDA-MB-231 breast cancer cells with GAP31 and MAP30 resulted in inhibition of cancer cell proliferation as well as inhibition of the expression of HER2 gene in vitro. When MDA-MB-231 human breast cancer cells were transferred into SCID mice, the mice developed extensive metastases and all mice succumbed to tumor by day 46. Treatment of the human breast cancer bearing SCID mice with GAP31 or MAP30 at 10 μg/injection EOD for 10 injections resulted in significant increases in survival, with 20-25% of the mice remaining tumor free for 96 days. Thus, antitumor agents GAP31 and MAP30 are effective against human breast cancer MDA-MB-231 in vitro and in vivo. There agents may therefore be of potential therapeutic use against breast carcinomas.

Original languageEnglish (US)
Pages (from-to)653-659
Number of pages7
JournalAnticancer Research
Issue number2 A
StatePublished - 2000
Externally publishedYes


  • Anti-tumor
  • Breast carcinoma
  • In vitro
  • Xenograft

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Inhibition of MDA-MB-231 human breast tumor xenografts and HER2 expression by anti-tumor agents GAP31 and MAP30'. Together they form a unique fingerprint.

Cite this